BIOMAT Database Logo BIOMAT Database Logo

Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study. 1993

T A Vandenberg, and K I Pritchard, and E A Eisenhauer, and M E Trudeau, and B D Norris, and P Lopez, and S S Verma, and R A Buckman, and A Muldal
Ontario Cancer Treatment and Research Foundation, London Regional Cancer Centre, London, Canada.

OBJECTIVE The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study to assess the efficacy and toxicity of edatrexate, a folate antagonist, in 35 patients with metastatic breast cancer. METHODS The planned dose of edatrexate was 80 mg/m2/wk administered intravenously as first-line therapy. Prior adjuvant chemotherapy was allowed provided at least 12 months had elapsed from the completion of treatment to the development of recurrence. RESULTS Mucositis was the dose-limiting toxicity in 34 assessable patients, resulting in a mean delivered dose-intensity of 57 mg/m2/wk. Other toxicities included myelosuppression, rash, pneumonitis, and increased AST. Side effects were generally mild to moderate. The complete plus partial remission rate (13 patients; 41%) was impressive. CONCLUSIONS Edatrexate is an active agent against metastatic breast cancer, with acceptable toxicity. A lower than planned delivered dose-intensity was mainly due to mucositis.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005493 Folic Acid Antagonists Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) Antifolate,Antifolates,Dihydrofolate Reductase Inhibitor,Folic Acid Antagonist,Dihydrofolate Reductase Inhibitors,Folic Acid Metabolism Inhibitors,Acid Antagonist, Folic,Acid Antagonists, Folic,Antagonist, Folic Acid,Antagonists, Folic Acid,Inhibitor, Dihydrofolate Reductase,Inhibitors, Dihydrofolate Reductase,Reductase Inhibitor, Dihydrofolate,Reductase Inhibitors, Dihydrofolate
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

T A Vandenberg, and K I Pritchard, and E A Eisenhauer, and M E Trudeau, and B D Norris, and P Lopez, and S S Verma, and R A Buckman, and A Muldal
A phase II study of weekly edatrexate (10-EDAM) in metastatic melanoma. A National Cancer Institute of Canada Clinical Trials Group study.
March 1993, Annals of oncology : official journal of the European Society for Medical Oncology,
T A Vandenberg, and K I Pritchard, and E A Eisenhauer, and M E Trudeau, and B D Norris, and P Lopez, and S S Verma, and R A Buckman, and A Muldal
Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
November 1986, Cancer treatment reports,
T A Vandenberg, and K I Pritchard, and E A Eisenhauer, and M E Trudeau, and B D Norris, and P Lopez, and S S Verma, and R A Buckman, and A Muldal
Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study.
September 1988, Investigational new drugs,
T A Vandenberg, and K I Pritchard, and E A Eisenhauer, and M E Trudeau, and B D Norris, and P Lopez, and S S Verma, and R A Buckman, and A Muldal
Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
February 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T A Vandenberg, and K I Pritchard, and E A Eisenhauer, and M E Trudeau, and B D Norris, and P Lopez, and S S Verma, and R A Buckman, and A Muldal
Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.
April 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T A Vandenberg, and K I Pritchard, and E A Eisenhauer, and M E Trudeau, and B D Norris, and P Lopez, and S S Verma, and R A Buckman, and A Muldal
Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).
June 2006, Annals of oncology : official journal of the European Society for Medical Oncology,
T A Vandenberg, and K I Pritchard, and E A Eisenhauer, and M E Trudeau, and B D Norris, and P Lopez, and S S Verma, and R A Buckman, and A Muldal
SarCNU in recurrent or metastatic colorectal cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
July 2006, Investigational new drugs,
T A Vandenberg, and K I Pritchard, and E A Eisenhauer, and M E Trudeau, and B D Norris, and P Lopez, and S S Verma, and R A Buckman, and A Muldal
Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.
October 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T A Vandenberg, and K I Pritchard, and E A Eisenhauer, and M E Trudeau, and B D Norris, and P Lopez, and S S Verma, and R A Buckman, and A Muldal
Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial.
February 2004, European journal of cancer (Oxford, England : 1990),
T A Vandenberg, and K I Pritchard, and E A Eisenhauer, and M E Trudeau, and B D Norris, and P Lopez, and S S Verma, and R A Buckman, and A Muldal
Phase II trial of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada clinical trials group study.
November 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!